Pregabalin is not a narcotic. The U.S. Drug Enforcement Administration explicitly classifies it with a “non-narcotic” designation. It belongs to a drug class called anticonvulsants, and it works through an entirely different mechanism than opioids or other narcotic painkillers. That said, pregabalin is a controlled substance due to its potential for misuse and dependence, which is likely why the question comes up so often.
How Pregabalin Is Classified
In the United States, pregabalin (brand name Lyrica) is a Schedule V controlled substance, the lowest tier of federal drug scheduling. The DEA’s controlled substances list marks it specifically as non-narcotic. For comparison, Schedule V is the same category as certain cough preparations containing small amounts of codeine. Narcotics like oxycodone, fentanyl, and morphine sit in Schedule II, several tiers higher.
The United Kingdom took a stricter approach. In 2018, pregabalin was classified as a Class C controlled drug under the Misuse of Drugs Act, placing it alongside anabolic steroids and some benzodiazepines. Prescriptions there now require specific documentation, record-keeping, and supervised destruction of unused supplies. This reclassification was driven by rising rates of misuse and pregabalin-related deaths in the UK.
Why It Works Differently Than Narcotics
Narcotics (opioids) relieve pain by binding to opioid receptors in the brain and spinal cord. Pregabalin does not interact with opioid receptors at all. It also has no activity at serotonin receptors, sodium channels, or the enzyme pathways that anti-inflammatory drugs target.
Instead, pregabalin binds to a specific protein on voltage-gated calcium channels in the nervous system. By attaching to this protein (called the alpha-2-delta subunit), it reduces the release of several chemical messengers that excite nerve cells. The practical effect is that overactive or damaged nerves quiet down, which is why pregabalin works for nerve pain, seizures, and anxiety disorders where the nervous system is essentially firing too much.
In a head-to-head trial comparing pregabalin to fentanyl (a powerful opioid) for nerve-related cancer pain, 73% of patients on pregabalin achieved at least a 30% pain reduction, compared with only 37% on fentanyl. Patients on pregabalin also reported higher satisfaction, while those on fentanyl had more side effects and were more likely to stop treatment. This illustrates that for certain types of pain, pregabalin can actually outperform narcotics while working through a completely different pathway.
What Pregabalin Treats
Pregabalin is FDA-approved for nerve pain caused by diabetes (diabetic neuropathy), nerve pain following shingles (postherpetic neuralgia), fibromyalgia, spinal cord injury pain, and as an add-on treatment for partial-onset seizures in adults. In Europe, it is also approved for generalized anxiety disorder. Doctors sometimes prescribe it off-label for other types of chronic pain or anxiety conditions.
Common Side Effects
Dizziness and drowsiness are the most frequent side effects, and they increase with dose. In clinical trials, about 31% of patients experienced dizziness (compared with 9% on placebo), and 22% experienced drowsiness (compared with 7% on placebo). At the highest approved dose of 600 mg per day, dizziness affected roughly one in four younger adults and one in three adults over 65.
Other notable side effects include:
- Peripheral edema (swelling in hands and feet): around 8% of patients, rising to 15-17% at higher doses
- Weight gain: about 9% of patients gained at least 7% of their body weight, compared with 2% on placebo
- Dry mouth: roughly 4% of patients, and appears to be dose-dependent
Older adults tend to experience these effects more frequently and at lower doses.
Dependence and Withdrawal Risk
Even though pregabalin is not a narcotic, it can cause physical dependence. This is one of the main reasons it carries a controlled substance designation. The risk of dependence rises with higher doses and longer use, but case reports show that even short courses at standard prescribed doses can lead to physical dependence in some people. Patients with a history of opioid use or substance abuse face a higher risk of misusing pregabalin.
Stopping pregabalin abruptly can trigger withdrawal symptoms including insomnia, nausea, headache, anxiety, excessive sweating, and diarrhea. More severe cases have involved tremors, hallucinations, suicidal thoughts, seizures, rapid heart rate, and elevated blood pressure. Because of this, the standard practice is to taper off pregabalin gradually rather than stopping all at once. If you’ve been taking it for more than a few weeks, reducing the dose slowly over at least a week is typical.
What Overdose Looks Like
Pregabalin overdose presents very differently from a narcotic overdose. With opioids, the primary danger is slowed or stopped breathing. With pregabalin, the most common symptoms are drowsiness (seen in about 62% of overdose cases), confusion (29%), and apathy (24%). Other reported symptoms include dizziness, unsteady movement, tremor, rapid heart rate, nausea, and blurred vision. Serious effects like coma or seizures are rare but have been documented, particularly when pregabalin is combined with other sedating substances. Losing consciousness or developing tremor after taking too much are signs that require immediate medical attention.
Why the Confusion Exists
Several factors blur the line in people’s minds. Pregabalin is a controlled substance, it treats pain, it can cause euphoria at high doses, and it carries dependence risk. These characteristics overlap with narcotics, even though the underlying pharmacology is fundamentally different. The word “narcotic” itself adds to the confusion. In everyday language, people often use it to mean any controlled or addictive drug, while in pharmacology it refers specifically to opioids. By either definition, pregabalin does not qualify: it is not an opioid, and federal regulators have explicitly marked it as non-narcotic in their scheduling documents.